MOLECULAR PARTNERS TO PRESENT AT THE COWEN AND COMPANY 35rd ANNUAL HEALTHCARE CONFERENCE Montag, 02. März 2015 - 08:58
 |
| Press Release (PDF) |
MOLECULAR PARTNERS TO PRESENT AT THE |
Zurich-Switzerland, 02 March 2015. Molecular Partners AG [SIX:MOLN] today announced that its CFO, Andreas Emmenegger, will present at the Cowen and Company 35th Annual Healthcare Conference on Tuesday 03 March 2015 at 8:00 AM Eastern Time (2:00 PM CET).
A copy of the presentation handout will be made available on the company's website:www.molecularpartners.com, within the Investors section. |
About Molecular Partners AG Molecular Partners is a biopharmaceutical company that is developing a new powerful class of therapies known as DARPins™.DARPins™ are potent, specific and versatile small protein therapies, which have the potential to offer benefits over conventional monoclonal antibodies or other currently available protein therapeutics. Molecular Partners has four compounds in various stages of clinical and preclinical development and several more in research, with a current focus on ophthalmology and oncology. Abicipar, the company’s lead product is expected to enter Phase III clinical trials in wet AMD with partner Allergan later this year. Molecular Partners has significant partnerships with pharmaceutical companies including Allergan, Roche and Janssen. For more information about the company, please visit: www.molecularpartners.com Notes: Molecular Partners raised CHF 106.2 million (thereof CHF 104.1 million proceeds from primary shares) in November 2014 noted as Europe's second largest biotech IPO of the year and the first biotech IPO in Switzerland in five years.
For further details, please contact:
Dr. Christian Zahnd, CEO
Andreas Emmenegger, CFO
Tel: +41 44 755 7700
Maria Patey
Tel: +44 (0)20 8877 8445 / +44 (0) 20 8877 8400
Rolf Schläpfer
Tel: +41 (0)43 344 4242 |